Sunsino Venture Group

Sunsino Venture Group is one of Taiwan's leading multi-asset alternative investment firms, founded in 1993 and headquartered in Taipei. Over a track record spanning more than three decades it has cumulatively managed 16 venture investment funds, including vehicles backed by Taiwan's government and National Development Council, and currently oversees roughly NT$4 billion, about US$150 million, in assets. The firm is led by Chairman and Managing Partner Vincent Wang, a Wharton MBA, chairman of the Taiwan Angel Investors Association and board member of the Taiwan Venture Capital Association, alongside Partner and STARTUP101 CEO Cami Lu. Sunsino invests in innovative and disruptive startups in healthcare, technology and software, with particular emphasis on AI, IoT, medtech and ESG companies that have working demos or MVPs validated by reputable industry players or initial sales. It also backs enterprise applications, food and agriculture tech and life sciences, supporting global entrepreneurs across its core markets of Taiwan, Japan, Korea, Southeast Asia and the United States. The firm writes cheques typically in the US$5 to 10 million range, investing from Series A through later growth rounds as a lead investor while advising founders on operating strategy, follow-on fundraising and exit planning. It has invested in over 200 companies with roughly 80 IPO and M&A outcomes; notable names include Cardival Medical, Loopd and Advanced Analogic Technologies. With three decades of fund management and a pan-Asian and US footprint, Sunsino Venture Group is an established growth-stage technology and healthcare investor.